RF Therapeutics Inc.




Financing And Exit Strategy

Early round financing has raised over $400,000 from family, friends and associates. This capital will take RF Therapeutics Inc. through the proof of principle stage.

A second round of financing is planned following the proof of principle in the fourth quarter of 2009. The pre-money valuation for this round is $2 million, based on similar net present value models. It is expected that we will need $3 million for chemical scale-up and formal pre-clinical testing, leading to Phase 1 clinical study in humans.

Our exit strategy, at this point, is to sell the technology to large pharma at the completion of a pilot study in humans. The company will continue to develop additional compounds in the pipeline for other applications such as PET and SPECT.